265 320
imaging necessary in addition to diffusion-weighted imaging?
Diagn Interv Radiol 2011;17:243–8.
[29]
Javali TD, Dwivedi DK, Kumar R, Jagannathan NR, Thulkar S, Dinda AK. Magnetic resonance spectroscopy imaging-directed transrectal ultrasound biopsy increases prostate cancer detection in men with prostate-specific antigen between 4-10 ng/mL and normal digital rectal examination: MRSI-directed TRUS biopsy in prostate cancer. Int J Urol 2014;21:257–62.[30]
Junker D, Scha¨fer G, Edlinger M, et al. Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspi- cion of prostate cancer. BioMed Res Int 2013;2013:252939.[31]
Kitajima K, Kaji Y, Fukabori Y, Yoshida K-I, Suganuma N, Sugimura K. Prostate cancer detection with 3 T MRI: comparison of diffusion- weighted imaging and dynamic contrast-enhanced MRI in combi- nation with T2-weighted imaging. J Magn Reson Imaging 2010;31:625–31.
[32]
Kumar V, Jagannathan NR, Kumar R, et al. Potential of 1 H MR spectroscopic imaging to segregate patients who are likely to show malignancy of the peripheral zone of the prostate on biopsy. J Magn Reson Imaging 2009;30:842–8.[33]
Kumar V, Jagannathan NR, Kumar R, et al. Transrectal ultrasound- guided biopsy of prostate voxels identified as suspicious of malig- nancy on three-dimensional1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 2007;20:11–20.[34]
Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guid- ed transperineal fusion biopsy for detection of prostate cancer. J Urol 2013;190:1380–6.
[35]
Labanaris AP, Engelhard K, Zugor V, Nu¨ tzel R, Ku¨ hn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis 2010;13:65–70.[36]
Lamb BW, Tan WS, Rehman A, et al. Is prebiopsy MRI good enough to avoid prostate biopsy?. A cohort study over a 1-year period. Clin Genitourin Cancer 2015;13:512–7.[37]
Matsuoka Y, Numao N, Saito K, et al. Combination of diffusion- weighted magnetic resonance imaging and extended prostate bi- opsy predicts lobes without significant cancer: application in pa- tient selection for hemiablative focal therapy. Eur Urol 2014;65:186–92.
[38]
Numao N, Yoshida S, Komai Y, et al. Usefulness of pre-biopsy multiparametric magnetic resonance imaging and clinical variables to reduce initial prostate biopsy in men with suspected clinically localized prostate cancer. J Urol 2013;190:502–8.[39]
Panebianco V, Barchetti F, Sciarra A, et al. Multiparametric mag- netic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study. Urol Oncol 2015;33, 17.e1–7.[40]
Panebianco V, Sciarra A, Ciccariello M, et al. Role of magnetic resonance spectroscopic imaging ([1H]MRSI) and dynamic con- trast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). La Radiol Med 2010;115:1314–29.[41]
Pepe P, Garufi A, Priolo G, Pennisi M. Can 3-Tesla pelvic phased- array multiparametric MRI avoid unnecessary repeat prostate bi- opsy in patients with PSA < 10 ng/mL? Clin Genitourin Cancer 2015;13:e27–30.[42]
Petrillo A, Fusco R, Setola SV, et al. Multiparametric MRI for prostate cancer detection: performance in patients with prostate-specific antigen values between 2.5 and 10 n g/mL. J Magn Reson Imaging 2014;39:1206–12.[43]
Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by trans- rectal ultrasound–guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without pre- vious prostate biopsies. Eur Urol 2014;66:22–9.
[44]
Porpiglia F, Russo F, Manfredi M, et al. The roles of multiparametric magnetic resonance imaging, PCA3 and Prostate Health Index— which is the best predictor of prostate cancer after a negative biopsy? J Urol 2014;192:60–6.[45]
Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology Scoring System for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol 2012;62:986–96.[46]
Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of trans- perineal template saturation prostate biopsy versus magnetic res- onance imaging targeted biopsy with magnetic resonance imaging- ultrasound fusion guidance. J Urol 2015;193:87–94.
[47]
Rais-Bahrami S, Siddiqui MM, Turkbey B, et al. Utility of multi- parametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol 2013;190:1721–7.[48]
Rouse P, Shaw G, Ahmed HU, Freeman A, Allen C, Emberton M. Multi-parametric magnetic resonance imaging to rule-in and rule- out clinically important prostate cancer in men at risk: a cohort study. Urol Int 2011;87:49–53.[49]
Roy C, Pasquali R, Matau A, Bazille G, Lang H. The role of diffusion 3- Tesla MRI in detecting prostate cancer before needle biopsy: multi- parametric study of 111 patients. J Radiol 2010;91:1121–8.[50]
Schmuecking M, Boltze C, Geyer H, et al. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisa- tion in prostate cancer? Int J Radiat Biol 2009;85:814–24.[51]
Sciarra A, Panebianco V, Cattarino S, et al. Multiparametric mag- netic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int 2012;110:1661–5.[52]
Sciarra A, Panebianco V, Ciccariello M, et al. Value of magnetic resonance spectroscopy imaging and dynamic contrast-enhanced imaging for detecting prostate cancer foci in men with prior nega- tive biopsy. Clin Cancer Res 2010;16:1875–83.
[53]
Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Research 2005;24:523–30.
[54]
Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4- 10 n g/mL: diagnostic efficacy of diffusion-weighted imaging, dy- namic contrast-enhanced MRI, and T2-weighted imaging. Am J Roentgenol 2011;197:664–70.[55]
Testa C, Schiavina R, Lodi R, et al. Accuracy of MRI/MRSI-based transrectal ultrasound biopsy in peripheral and transition zones of the prostate gland in patients with prior negative biopsy. NMR Biomed 2010;23:1017–26.
[56]
Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol 2014;192:67–74.[57]
Vinet M, Vlaeminck-Guillem V, Rouvie`re O, et al. Le score PCA3 et l’IRM prostatique permettent-ils de se´lectionner les patients can- didats a une premie`re se´rie de biopsies prostatiques? Prog Urol 2013;23:121–7.
[58]
Wang R, Wang H, Zhao C, et al. Evaluation of multiparametric magnetic resonance imaging in detection and prediction of prostate cancer. PLoS One 2015;10:e0130207.[59]
Watanabe Y, Terai A, Araki T, et al. Detection and localization of prostate cancer with the targeted biopsy strategy based on ADCE U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 2 5 0 – 2 6 6
265